Terumo Begins Commercial Distribution of BSD`s MicroThermX Microwave Ablation System at ECIO Following Successful Training of Sales Personnel

SALT LAKE CITY--(BUSINESS WIRE)--July 8, 2013--BSD Medical Corporation (the "Company" or "BSD") reports completion of intensive training of Terumo sales personnel in preparation for the commercial launch by Terumo Europe NV (Terumo) of BSD's MicroThermX Microwave Ablation System (MicroThermX) at the European Conference on Interventional Oncology (ECIO). BSD and Terumo conducted successful training of 80 Terumo sales personnel prior to the commercial launch. The increasing role of microwave ablation and MicroThermX were featured at ECIO. Terumo and BSD co-sponsored an educational symposium and workshops highlighting the MicroThermX, which were well attended and led to many potential customer contacts. ECIO is a comprehensive international meeting focused exclusively on the rapidly growing field of interventional oncology, a key market for BSD's microwave ablation products. Leading interventional oncology experts from over 60 countries attended the conference.

"The ECIO meeting significantly increased the profile of the Company's line of microwave ablation products," stated Sam Maravich, VP of Sales and Marketing BSD. "The tremendous success of the MicroThermX exhibit was evident by a constant stream of interested clinicians from around the world. The success of the meeting reflects the dynamic growth of microwave ablation throughout the world."